Oral Session 3-11C ATL: Prognostic Factors

[OS3-11C-2] Proposal of risk-adapted therapy for ATL with the ATL-PI: a supplementary analysis of JCOG9801

Kosuke Toyoda¹, Kunihiro Tsukasaki², Ryunosuke Machida³, Tomohiro Kadota³, Takuya Fukushima⁴, Kenji Ishitsuka⁵, Dai Maruyama⁶, Hirokazu Nagai⁷ (1.Hematol., Rheumatol. and Infectious Diseases, Kumamoto Univ., Kumamoto, Japan, 2.Hematol., International Medical Center, Saitama Medical Univ., Saitama, Japan, 3.JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan, 4.Lab. of Hematoimmunology, Univ. of the Ryukyus, Okinawa, Japan, 5.Hematol. and Immunol., Kagoshima Univ. Hospital, Kagoshima, Japan, 6.Hematol., National Cancer Center Hospital, Tokyo, Japan, 7.Hematol., National Hospital Organization Nagoya Medical Center, Nagoya, Japan)